DA
Deep Apple Therapeutics at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Deep Apple Therapeutics brings 4 presentations to ObesityWeek 2026 in National Harbor. Its work here centers on early drug discovery for obesity, including oral small molecules that block or activate the GIP receptor and a dual MC4R and MC3R agonist. It also pairs high-throughput cryo-EM with AI foundation models to find amylin receptor drugs.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
DA Deep Apple Therapeutics | |
Drug discovery company using cryo-EM and AI to find oral small molecules for obesity targets such as MC4R, GIPR and amylin receptors. | Poster Sat Nov 14 7:30pm–8:30pm Discovery of DAT-9232: A Highly Selective Dual MC4R/MC3R Agonist with Balanced Signaling Profiles Metabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Integrating High-Throughput Cryo-EM and AI Foundation Models for Amylin Receptor Drug Discovery Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Discovery of DAT-004, an Oral Small-Molecule GIP Receptor Antagonist for the Treatment of Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Mon Nov 16 2:30pm–3:30pm Structure-Based Discovery of Novel Orthosteric and Allosteric GIP-R Agonists for Metabolic Therapy Chronic disease and obesity complications |
Find decision makers at Deep Apple Therapeutics
Tell us what you sell and we’ll find the people at Deep Apple Therapeutics most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction